RemeGen Co., Ltd. (HKG:9995)

Market Cap	50.32B
Revenue (ttm)	2.43B
Net Income (ttm)	-1.04B
Shares Out	555.94M
EPS (ttm)	-1.91
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,162,400
Average Volume	5,150,515
Open	79.75
Previous Close	78.25
Day's Range	76.05 - 79.95
52-Week Range	11.52 - 126.60
Beta	0.86
RSI	42.61
Earnings Date	Mar 26, 2026

About RemeGen

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of various cancers. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial gro...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 2,999
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9995

Financial Performance

In 2024, RemeGen's revenue was 1.72 billion, an increase of 58.54% compared to the previous year's 1.08 billion. Losses were -1.47 billion, -2.84% less than in 2023.

Financial numbers in CNY